These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 19844788)

  • 1. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.
    Ellis MJ; Lin L; Crowder R; Tao Y; Hoog J; Snider J; Davies S; DeSchryver K; Evans DB; Steinseifer J; Bandaru R; Liu W; Gardner H; Semiglazov V; Watson M; Hunt K; Olson J; Baselga J
    Breast Cancer Res Treat; 2010 Jan; 119(2):379-90. PubMed ID: 19844788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.
    Liedtke C; Cardone L; Tordai A; Yan K; Gomez HL; Figureoa LJ; Hubbard RE; Valero V; Souchon EA; Symmans WF; Hortobagyi GN; Bardelli A; Pusztai L
    Breast Cancer Res; 2008; 10(2):R27. PubMed ID: 18371219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.
    Sabine VS; Crozier C; Brookes CL; Drake C; Piper T; van de Velde CJ; Hasenburg A; Kieback DG; Markopoulos C; Dirix L; Seynaeve C; Rea DW; Bartlett JM
    J Clin Oncol; 2014 Sep; 32(27):2951-8. PubMed ID: 25071141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting endocrine therapy responsiveness in breast cancer.
    Ma CX; Sanchez CG; Ellis MJ
    Oncology (Williston Park); 2009 Feb; 23(2):133-42. PubMed ID: 19323294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.
    López-Knowles E; Segal CV; Gao Q; Garcia-Murillas I; Turner NC; Smith I; Martin LA; Dowsett M
    Breast Cancer Res; 2014 Jun; 16(3):R68. PubMed ID: 24981670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations.
    Schwartzberg LS; Vidal GA
    Clin Breast Cancer; 2020 Aug; 20(4):e439-e449. PubMed ID: 32278641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy.
    Chen S; Huang L; Chen CM; Shao ZM
    Oncotarget; 2015 Jul; 6(20):18174-82. PubMed ID: 26053183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
    Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
    Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III
    Ma CX; Suman V; Goetz MP; Northfelt D; Burkard ME; Ademuyiwa F; Naughton M; Margenthaler J; Aft R; Gray R; Tevaarwerk A; Wilke L; Haddad T; Moynihan T; Loprinzi C; Hieken T; Barnell EK; Skidmore ZL; Feng YY; Krysiak K; Hoog J; Guo Z; Nehring L; Wisinski KB; Mardis E; Hagemann IS; Vij K; Sanati S; Al-Kateb H; Griffith OL; Griffith M; Doyle L; Erlichman C; Ellis MJ
    Clin Cancer Res; 2017 Nov; 23(22):6823-6832. PubMed ID: 28874413
    [No Abstract]   [Full Text] [Related]  

  • 12. Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.
    Guarneri V; Generali DG; Frassoldati A; Artioli F; Boni C; Cavanna L; Tagliafico E; Maiorana A; Bottini A; Cagossi K; Bisagni G; Piacentini F; Ficarra G; Bettelli S; Roncaglia E; Nuzzo S; Swaby R; Ellis C; Holford C; Conte P
    J Clin Oncol; 2014 Apr; 32(10):1050-7. PubMed ID: 24590635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR
    Mollon LE; Anderson EJ; Dean JL; Warholak TL; Aizer A; Platt EA; Tang DH; Davis LE
    Clin Breast Cancer; 2020 Jun; 20(3):e232-e243. PubMed ID: 32234362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2- BC patients with residual disease after neoadjuvant chemotherapy: a cohort study.
    Miglietta F; Carraro V; Amato O; Griguolo G; Bottosso M; Munari G; Zarrilli G; Lo Mele M; Barbieri C; Dei Tos AP; Guarneri V; Dieci MV; Fassan M
    J Clin Pathol; 2024 Sep; 77(10):690-696. PubMed ID: 37344170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial.
    Ellis MJ; Miller WR; Tao Y; Evans DB; Chaudri Ross HA; Miki Y; Suzuki T; Sasano H
    Breast Cancer Res Treat; 2009 Jul; 116(2):371-8. PubMed ID: 18941892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
    Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
    Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of PIK3CA mutations and PTEN expression on the effect of neoadjuvant therapy for postmenopausal luminal breast cancer patients.
    Hayama S; Nakamura R; Ishige T; Sangai T; Sakakibara M; Fujimoto H; Ishigami E; Masuda T; Nakagawa A; Teranaka R; Ota S; Itoga S; Yamamoto N; Nagashima T; Otsuka M
    BMC Cancer; 2023 Apr; 23(1):384. PubMed ID: 37106324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
    Ellis MJ; Suman VJ; Hoog J; Goncalves R; Sanati S; Creighton CJ; DeSchryver K; Crouch E; Brink A; Watson M; Luo J; Tao Y; Barnes M; Dowsett M; Budd GT; Winer E; Silverman P; Esserman L; Carey L; Ma CX; Unzeitig G; Pluard T; Whitworth P; Babiera G; Guenther JM; Dayao Z; Ota D; Leitch M; Olson JA; Allred DC; Hunt K
    J Clin Oncol; 2017 Apr; 35(10):1061-1069. PubMed ID: 28045625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer.
    Jones RL; Salter J; A'Hern R; Nerurkar A; Parton M; Reis-Filho JS; Smith IE; Dowsett M
    Breast Cancer Res Treat; 2010 Jan; 119(2):315-23. PubMed ID: 19247830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
    Ramirez-Ardila DE; Helmijr JC; Look MP; Lurkin I; Ruigrok-Ritstier K; van Laere S; Dirix L; Sweep FC; Span PN; Linn SC; Foekens JA; Sleijfer S; Berns EM; Jansen MP
    Breast Cancer Res Treat; 2013 May; 139(1):39-49. PubMed ID: 23592373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.